Evidence map›Paper›PMID 36645751›Full record

ReviewBMJ paediatrics open2022

Notes for the general paediatrician: managing thyrotoxicosis in children and young people.

Marianna Vidouris, Christopher Worth, Leena Patel, Anjali Date, Anas Jasser, Beverly Hird, Lesley Tetlow, Indraneel Banerjee

Open access · diamondAbstract readReview
In one paragraph

Review in BMJ paediatrics open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Marianna VidourisDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital. Manchester University NHS Foundation Trust, Manchester, UK marianna.vidouris@nhs.net.ORCID 0000-0002-0801-9000
Christopher WorthDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital. Manchester University NHS Foundation Trust, Manchester, UK.
Leena PatelDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital. Manchester University NHS Foundation Trust, Manchester, UK.
Anjali DateNorth West Paediatric Endocrine Network (NOWPEN), Manchester, UK.
Anas JasserNorth West Paediatric Endocrine Network (NOWPEN), Manchester, UK.
Beverly HirdDepartment of Clinical Biochemistry, Manchester University NHS Foundation Trust, Manchester, UK.ORCID 0000-0002-7173-6862
Lesley TetlowDepartment of Clinical Biochemistry, Manchester University NHS Foundation Trust, Manchester, UK.
Indraneel BanerjeeDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital. Manchester University NHS Foundation Trust, Manchester, UK.
Manchester University NHS Foundation Trust · GBUniversity of Manchester · GBEast Lancashire Hospitals NHS Trust · GBTameside Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyrotoxicosis due to hyperthyroidism is a serious disorder in childhood often presenting to general paediatricians with a range of clinical manifestations. The commonest cause is Graves' disease, an autoimmune disorder resulting from thyrotropin receptor stimulation by autoantibodies. Early recognition and accurate interpretation of investigations are essential to achieve and maintain a euthyroid state. This will not only optimise growth, development and transition from childhood to young adult life but also avoid the potentially severe and life-threatening complications of acute thyrotoxicosis. In this review, we have focussed on the general paediatrician's perspective of the presentation and management of thyrotoxicosis and the need to network with specialist paediatric endocrine centres to optimise patient care. We have discussed nuances of therapy, side effects and long-term outcomes, while recognising that limited remission rates in this age group often necessitate more definitive management. While carbimazole is usually used as first-line medical therapy, we have provided useful information to guide paediatricians in the discussion of individualised safe and effective treatment plans for both short-term and long-term management.

Indexed as

Graves DiseaseHyperthyroidismThyrotoxicosisAdolescentAntithyroid AgentsCarbimazoleChildHumansYoung AdultAntithyroid AgentsCarbimazoleEndocrinology

Identifiers

PMID36645751
PMCPMC9685199
OpenAlexW4309592859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.